in a move aimed at revolutionizing the early detection of psoriatic arthritis (psa) in canada, novartis pharmaceuticals canada has announced a partnership with clarius mobile health to improve access to handheld ultrasound devices for rheumatologists.
this collaboration aims to provide the right tools and training to rheumatologists in order to identify diagnostic markers of psa earlier, potentially accelerating the diagnosis timeline for patients.
“more than half of patients with psa are waiting two or more years for a diagnosis, and many report that they are unsatisfied with the current diagnostic delay in psa, and if undetected, it could cause irreversible joint damage in as little as six months. by improving access to point-of-care ultrasound technology, rheumatologists will be able to identify diagnostic markers soon, which may positively impact the timeline to diagnosis of psa,” mark vineis, country president, novartis canada said in an email to healthing.
“we recognize the tremendous potential ai holds for our industry and the healthcare landscape at large, and by joining forces with clarius, we’re pioneering a new era of healthcare collaboration, showcasing the power of cross-sector partnerships and improving accessibility to medical imaging in canada.”